The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs

被引：0
|
作者：
Jeffrey Cummings
机构：
[1] University of Nevada Las Vegas,Department of Brain Health, School of Integrated Health Sciences
[2] Cleveland Clinic Lou Ruvo Center for Brain Health,undefined
来源：
The Journal of Prevention of Alzheimer's Disease | 2020年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：288 / 290
页数：2
相关论文
共 50 条
  • [21] SECONDARY PREVENTION TRIALS IN PRECLINICAL ALZHEIMER'S DISEASE
    Sperling, Reisa
    NEUROBIOLOGY OF AGING, 2016, 39 : S16 - S16
  • [22] Integrating ADNI results into Alzheimer's disease drug development programs
    Cummings, Jeffrey L.
    NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1481 - 1492
  • [23] Measuring cognitive change in Alzheimer's disease clinical drug trials
    Harrison, J. E.
    JOURNAL OF NUTRITION HEALTH & AGING, 2007, 11 (04): : 327 - 329
  • [24] A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease
    Rachel F. Buckley
    Victor L. Villemagne
    Colin L. Masters
    Kathryn A. Ellis
    Christopher C. Rowe
    Keith Johnson
    Reisa Sperling
    Rebecca Amariglio
    Journal of Molecular Neuroscience, 2016, 60 : 354 - 361
  • [25] A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease
    Buckley, Rachel F.
    Villemagne, Victor L.
    Masters, Colin L.
    Ellis, Kathryn A.
    Rowe, Christopher C.
    Johnson, Keith
    Sperling, Reisa
    Amariglio, Rebecca
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2016, 60 (03) : 354 - 361
  • [26] MRI-Based Screening of Preclinical Alzheimer's Disease for Prevention Clinical Trials
    Casamitjana, Adria
    Petrone, Paula
    Tucholka, Alan
    Falcon, Carles
    Skouras, Stavros
    Luis Molinuevo, Jose
    Vilaplana, Veronica
    Domingo Gispert, Juan
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 (04) : 1099 - 1112
  • [27] Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations
    Bukhari, Syed Nasir Abbas
    CURRENT DRUG DELIVERY, 2022, 19 (01) : 17 - 31
  • [28] Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials
    Grill, Joshua D.
    Zhou, Yan
    Elashoff, David
    Karlawish, Jason
    NEUROBIOLOGY OF AGING, 2016, 39 : 147 - 153
  • [29] Pathology of clinical and preclinical Alzheimer's disease
    Thal, Dietmar Rudolf
    von Arnim, Christine
    Griffin, W. Sue T.
    Yamaguchi, Haruyasu
    Mrak, Robert E.
    Attems, Johannes
    Upadhaya, Ajeet Rijal
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2013, 263 : S137 - S145
  • [30] Pathology of clinical and preclinical Alzheimer’s disease
    Dietmar Rudolf Thal
    Christine von Arnim
    W. Sue T. Griffin
    Haruyasu Yamaguchi
    Robert E. Mrak
    Johannes Attems
    Ajeet Rijal Upadhaya
    European Archives of Psychiatry and Clinical Neuroscience, 2013, 263 : 137 - 145
12345